首页|慢性髓性白血病伴附加染色体异常疗效及预后的相关性分析

慢性髓性白血病伴附加染色体异常疗效及预后的相关性分析

扫码查看
目的 探讨初诊时伴附加染色体异常(ACAs)的慢性髓性白血病(CML)慢性期(CML-CP)患者与疾病的诊疗、进展及预后的相关性。方法 回顾性分析2016年1月1日至2022年12月31日该院收治的92例初诊CML-CP患者的临床资料,分析其临床及遗传学特征,采用Kaplan-Meier法分析伴或不伴ACAs的CML-CP患者生存分布的差异,探讨CML-CP伴ACAs患者与疾病诊疗及预后的相关性。结果 92例CML-CP患者初诊骨髓象中均检出BCR-ABL1融合基因(阳性率为100%),其中单纯t(9;22)患者82例(89。13%),ACAs患者10例(10。87%)。CML-CP患者生存时间78。49~87。64个月,中位83。06个月。与单纯t(9;22)患者比较,ACAs患者发病年龄、总生存期均更低,且具有更高的感染风险,差异均有统计学意义(P<0。05)。伴ACAs是CML-CP患者预后不良的独立危险因素。结论 ACAs可能是导致CML疾病进展和预后不良的因素之一。
Correlation analysis of therapeutic effect and prognosis of chronic myeloid leukemia with additional chromosomal abnormalities
Objective To explore the correlation between the diagnosis,treatment,progression and prognosis of chronic myeloid leukemia(CML)in chronic phase(CML-CP)patients with additional chromo-somal abnormalities(ACAs)at the initial diagnosis.Methods The clinical data of 92 patients with newly di-agnosed CML-CP admitted to the hospital from January 1,2016 to December 31,2022 were retrospectively an-alyzed.The clinical and genetic characteristics were analyzed.Kaplan Meier method was used to analyze the differences in survival distribution of CML-CP patients with or without ACAs,and to explore the correlation between CML-CP patients with ACAs and disease diagnosis,treatment,and prognosis.Results BCR-ABL1 fusion gene was detected in the initial bone marrow images of 92 CML-CP patients(100%positive rate),with 82 cases(89.13%)in the pure t(9;22)group and 10 cases(10.87%)in the ACAs group.The survival time of CML-CP patients was 78.49-87.64 months,with a median of 83.06 months.Compared with simple t(9;22),the onset age and overall survival time of ACAs patients were lower,and they had a higher risk of infection,and the differences were statistically significant(P<0.05).ACAs were independent risk factors for poor prognosis in CML-CP patients.Conclusion ACAs may be one of the factors leading to the progression and poor prognosis of CML.

Chronic myeloid leukemiaAdditional chromosomal abnormalitiesTreatment out-comePrognosisCorrelational study

闫利、安福润、杨冬冬、翟志敏

展开 >

安徽医科大学第二附属医院血液内科,安徽 合肥 230601

慢性髓性白血病 附加染色体异常 治疗结果 预后 相关性研究

国家自然科学基金项目安徽省科技重大专项基金项目

81670179201903a07020030

2024

现代医药卫生
重庆市卫生信息中心

现代医药卫生

影响因子:0.758
ISSN:1009-5519
年,卷(期):2024.40(17)